Christelle Chedrawy MD, Abstract Co-Author: Nothing to Disclose

Daniel Anthony Falco DO, Abstract Co-Author: Nothing to Disclose

Bimal Bharatkumar Patel DO, Abstract Co-Author: Nothing to Disclose

Pedram Rezai MD, Presenter: Nothing to Disclose

Surgical resection remains the treatment of choice for hepatocellular carcinoma (HCC) and metastatic liver cancer (MLC). However, only up to 25% of the patients are surgical candidates. Consequently, the majority of these patients are treated with systemic chemotherapeutic agents or locoregional therapies. The objective of this presentation is to discuss different imaging biomarkers of treatment response evaluation in HCC and MLC.

An overview of anatomical imaging biomarkers such as WHO, RECIST and volumetric evaluation will be provided. Biomarkers that monitor alterations in function of neoplastic cell in response to treatment such as EORTC and DWI MR will be discussed. Eventually, liver-specific biomarkers of treatment response such as mRECIST, EASL and Choi criteria will be discussed.

http://abstract.rsna.org/uploads/2014/14007589/14007589_bfco.pdf

Chedrawy, C, Falco, D, Patel, B, Rezai, P, What Interventional Radiologist Needs to Know about Treatment Response Evaluation of Liver Malignancies in Response to Locoregional Therapies.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14007589.html